Mitsubishi UFJ Asset Management Co. Ltd. Has $9.74 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Key Points

• Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Illumina, Inc. by 7.5%, acquiring a total of 122,715 shares valued at approximately $9.7 million.
• Illumina reported earnings per share (EPS) of $1.19 for the last quarter, beating analysts' expectations, although revenue of $1.06 billion was down 4.8% compared to the previous year.
• The stock has received mixed ratings from analysts, with a consensus rating of "Hold" and a price target averaging around $127.74.

Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 7.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 122,715 shares of the life sciences company's stock after acquiring an additional 8,536 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.08% of Illumina worth $9,736,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cerity Partners LLC lifted its stake in Illumina by 5.0% in the fourth quarter. Cerity Partners LLC now owns 25,290 shares of the life sciences company's stock valued at $3,361,000 after buying an additional 1,214 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Illumina in the 4th quarter valued at about $50,577,000. Sterling Capital Management LLC boosted its stake in Illumina by 20.9% during the 4th quarter. Sterling Capital Management LLC now owns 17,118 shares of the life sciences company's stock valued at $2,287,000 after purchasing an additional 2,960 shares during the period. Rockefeller Capital Management L.P. grew its position in Illumina by 6.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 185,220 shares of the life sciences company's stock worth $24,751,000 after purchasing an additional 10,568 shares during the last quarter. Finally, Townsquare Capital LLC increased its stake in shares of Illumina by 23.5% in the fourth quarter. Townsquare Capital LLC now owns 16,196 shares of the life sciences company's stock valued at $2,164,000 after purchasing an additional 3,087 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ILMN. Stephens set a $110.00 price objective on Illumina and gave the stock an "overweight" rating in a research report on Monday, August 4th. Wall Street Zen lowered Illumina from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Guggenheim lowered their price target on Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group upped their price objective on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a report on Friday, August 1st. Finally, Royal Bank Of Canada raised their target price on shares of Illumina from $118.00 to $126.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Illumina has a consensus rating of "Hold" and an average target price of $124.58.

Illumina Stock Down 1.0%

Shares of ILMN traded down $1.02 during trading hours on Thursday, reaching $100.09. The company's stock had a trading volume of 1,312,223 shares, compared to its average volume of 2,373,857. The company has a 50 day moving average of $96.10 and a two-hundred day moving average of $90.64. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The firm has a market cap of $15.38 billion, a price-to-earnings ratio of 12.67, a P/E/G ratio of 2.19 and a beta of 1.37. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina's revenue was down 4.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.36 EPS. As a group, research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.